Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.
GSK taps Royal Bank of Scotland chair Philip Hampton to lead its own board
It's official: GlaxoSmithKline ($GSK) tapped Royal Bank of Scotland chair Philip Hampton to take the reins as chairman. The choice comes as increasingly restive shareholders call for change at the drugmaker, plagued by corruption scandals and suffering from competition to its megablockbuster respiratory drug Advair. He'll join GSK's board Jan. 1, become deputy chair in April and move into Chairman Christopher Gent's seat in September 2015. Report
Biotech > Sam Waksal has appointed his brother, Harlan Waksal, as CEO of his new biotech venture, Kadmon. Waksal, once convicted in an insider trading scandal related to ImClone, a biotech he founded, was banned from serving as a director of a public company. He will serve instead as Kadmon's head of innovation, science and strategy. Story > Paul Stinson has been appointed BioAlberta's new president and CEO. Release > Dr. Adam Koppel has joined Trevena's ($TRVN) board of directors, replacing Christopher Mirabelli. Release > Merus Labs International's CEO, Elie Farah, stepped down from his spot at the helm, to be replaced by Barry Fishman in the interim. Release > Transgene appointed Eric Quéméneur as its executive VP of R&D. Release > Azita Nejad joined ReVance Therapeutics as VP of quality. Release > Avillion appointed Jarrod Longcor as its chief business officer. Release > BioLife Solutions brought on Jason Acker and Anthony Davies to join its scientific advisory board. Release > Avalanche Biotechnologies appointed Dr. Roman Rubio as senior VP and head of translational medicine. Release > Olivier Danos joined Biogen Idec ($BIIB) as its senior VP of gene therapy. Release > Ophthotech ($OPHT) named Michael Atieh as its executive VP and chief financial and business officer. Release > Protein Technologies hired Nate Cosper as its president and CEO. Release > Celladon appointed Scott Garrett as its VP of commercial planning. Release > ChemoCentryx ($CCXI) brought on Dr. Israel Charo as its senior VP of research. Release > Synageva Biopharma appointed Robert Bazemore as its chief operating officer. Release > Michel Bouvier will be the new scientific advisory board chairman at Domain Therapeutics. Release > RainDance Technologies named Fritz Eibel its senior VP of strategic marketing. Release > Cerebain Biotech brought on Miriam Weber Miller as its corporate vice president. Release > Coherus BioSciences has appointed Mary Szela to its board of directors. Release > Pfenex ($PFNX) has appointed Robin Campbell to its board of directors. Release Pharma > Valeant Pharmaceuticals ($VRX) has appointed Jeffrey Ubben as a director of the board. Release Biotech IT > Medidata ($MDSO) has appointed Michael Capone as chief operating officer. Release |
||||||||||
